EOLS · Evolus, Inc. · Stock research

Current Thesis

Evolus is being repriced from a cash-burning single-product toxin challenger into a two-category injectables business that now generates positive adjusted EBITDA. The 2026-08-05 Q2 print delivered net revenue of $84.1M (+21% YoY) against a consensus near $81.6M, a third consecutive quarter of positive adjusted EBITDA at $4.7M (a $12.6M YoY swing), and a raised FY2026 revenue floor ($330–337M, up from $327–337M). Price responded: the 2026-08-14 close of $8.15 sits 2.2% under the 52-week high of $8.34 after a 25.5% three-month advance. The leg being bought is margin inflection plus a filler franchise attaching to an existing 18,000-account toxin base — not a pipeline event. Nothing company-confirmed resolves it inside the next 30 days.

Bullish and bearish views on Evolus, Inc.

The model's bull view on Evolus, Inc. (EOLS), in brief: Q2 2026 (2026-08-05): net revenue $84.1M, +21% YoY, above the ~$81.6M consensus, with FY2026 guidance raised to $330–337M and adjusted gross margin guidance lifted to 67.0–67.5%; non-GAAP opex narrowed to $212–216M. The bear view: The revenue beat came with a wider bottom-line loss: adjusted EPS of -$0.12 versus a -$0.04 consensus (2026-08-05). Both cases follow in full.

Bull Case

• Q2 2026 (2026-08-05): net revenue $84.1M, +21% YoY, above the ~$81.6M consensus, with FY2026 guidance raised to $330–337M and adjusted gross margin guidance lifted to 67.0–67.5%; non-GAAP opex narrowed to $212–216M.
• Adjusted EBITDA $4.7M in Q2, a $12.6M improvement versus the year-ago quarter — the third straight positive quarter. The operating leverage argument is now evidenced by prints rather than by a model.
• 2028 framework reaffirmed on the same call: $450–500M net revenue, 13–15% adjusted EBITDA margin, international above 15% of revenue, Jeuveau at mid-teens US share, Evolysse at high-single-digit share.
• Cross-sell is measurable: per the Q2 deck, accounts buying both Jeuveau and Evolysse purchased 2.5x more volume year-to-date than single-product accounts.

• Geographic expansion, 2026-08-03/04: the Symatese Aesthetics licence was amended to add Canada, Australia and New Zealand for the full Estyme HA gel line. Terms were not disclosed, so the revenue contribution is not quantifiable from the release.
• Sell-side sits far above spot: consensus average target $14.50 with 4 buy / 1 hold / 1 sell tracked as of 2026-08-11; BTIG maintained a buy with a $13.00 target on 2026-06-17.

Bear Case

• The revenue beat came with a wider bottom-line loss: adjusted EPS of -$0.12 versus a -$0.04 consensus (2026-08-05). Positive adjusted EBITDA and a widening per-share loss coexisted in the same quarter.
• Guidance implies H2 deceleration. FY2026 of $330–337M represents 11–13% growth for the full year against Q2's +21%. The second half has to slow materially for the guide to be met as given.
• Q2 adjusted gross margin of 69% included roughly 120 basis points of tariff refund benefit — the FY guide of 67.0–67.5% sits below the reported quarter, so the margin optics do not repeat automatically.
• Balance sheet is thin relative to spend: cash and equivalents of $45.2M at 2026-06-30 against FY non-GAAP opex guidance of $212–216M. A Form S-3 shelf covering up to $250M of common, preferred, debt, warrants, units and rights is on file, so issuance into a 52-week-high tape requires no new registration.
• The 2028 bridge requires re-acceleration. Getting from FY2026 guidance of $330–337M to the 2028 target of $450–500M demands a growth rate well above the 11–13% guided for this year, and the reaffirmation is unaccompanied by a dated proof point before the Q3 print.
• Competitive floor: the US toxin market now carries several value-tier entrants alongside Allergan's Botox, and Jeuveau's share is the single most important line in the model. A flat share number in the Q3 deck removes the share-gain leg entirely.

Setup & Price Structure

The 2026-08-14 close of $8.15 is 2.2% below the 52-week high of $8.34, with a 25.5% three-month return. RSI(14) reads 78.9 — above the conventional 70 overbought threshold and consistent with an unbroken post-print advance rather than a consolidation.

The moving-average structure as of 2026-08-11: 50-day at $6.52, 200-day at $5.56, both rising, with price extended well above each. A new one-year high printed on 2026-08-11, six sessions after the Q2 report. The $6.50 area — the 50-day average and the upper part of the pre-print range — is the first structural shelf beneath spot; the post-2026-08-05 gap is the feature that would be surrendered on a retreat through it.

Positioning observables, stated as observables: institutional ownership of 90.69% and a market capitalisation of $527.74M as of 2026-08-11; six tracked sell-side ratings with an average target of $14.50, far above the market price, which is the signature of thin coverage rather than a crowded consensus; no earnings date inside the next 30 days, so there is no imminent print to position into or out of. Form 4 activity in the record reviewed consists of restricted-stock grants and share withholding for tax obligations; no August 2026 discretionary open-market insider sale surfaced. The live issuance risk is the $250M shelf, not disclosed insider distribution.

Narrative life-cycle: ACCELERATING. Dating it — 2026-08-03/04 territory expansion, 2026-08-05 beat-and-raise with a third consecutive positive adjusted EBITDA quarter, 2026-08-11 new one-year high, price 2.2% off the 52-week high on 2026-08-14. New headlines are arriving and the price is making highs, while mainstream coverage remains thin. What argues against calling it mature is the coverage count; what argues against fresh entry here is the RSI and the distance above both averages.

Catalyst Calendar (next 30 days)

• 2026-08-15 to 2026-09-14: no company-confirmed dated event. Q2 results were released 2026-08-05 and the Q2 10-Q (period ended 2026-06-30) is filed. The window is a catalyst void; the stock trades on tape and category read-across only.
• ~2026-10-30 (est.) — AbbVie Q3 print. Allergan Aesthetics commentary is the read-across on US facial-injectables category volume.
• ~2026-11-04 (est.) — Q3 2026 results. First test of whether the H2 implied by $330–337M is a deceleration or conservatism.
• ~2026-12-31 (est.) — Evolysse Sculpt US approval, guided by management as expected by end of 2026 in the Q2 deck. Undated by the FDA in public disclosure.

What Would Change Our Mind

The structural break is the post-earnings gap. A weekly close below $6.50 returns price to the pre-print range and under the 50-day average, which removes the entire re-rating leg the 2026-08-05 beat created and leaves the story where it was in June.

On fundamentals, three specific datapoints would flip the read. A Q3 print (~2026-11-04, est.) showing revenue growth below 11% would confirm that the FY guide's implied H2 slowdown is demand, not conservatism. An adjusted gross margin below 67% without a tariff-refund offset would show the 69% Q2 figure was a one-quarter artefact. A prospectus supplement or 8-K announcing a common-stock offering off the $250M shelf while price sits near the highs would reprice the equity story around dilution rather than around EBITDA inflection.

Conversely, a Jeuveau share number above 14% in the Q3 deck plus a fourth consecutive positive adjusted EBITDA quarter would extend the leg rather than break it.

Correlation Notes

• Aesthetics category beta: EOLS trades against AbbVie's Allergan Aesthetics disclosures and Galderma's results, which set the tone for US facial-injectable volume. Category softness at either shows up in Evolus's account-level ordering with a lag.
• Medspa capex: aesthetic capital-equipment names (InMode, Cutera) are a proxy for practice-level financial health, which is upstream of consumable toxin and filler reorders.
• Import-duty exposure: Q2 adjusted gross margin carried roughly 120 basis points of tariff refund benefit, tying the P&L directly to duty treatment of imported product. Trade-policy headlines on Korean pharmaceutical imports are a live margin input, not background noise.
• Small-cap beta: at a $527.74M market capitalisation (2026-08-11) the name moves with Russell 2000 and XBI risk appetite independent of company news, which widens the range around any single print.
• Consumer discretionary: injectables are cash-pay procedures. Deterioration in discretionary services spend transmits to unit volume faster than to the reported quarter, because loyalty-programme redemptions lead invoiced revenue.